Foresite Sees Plenty Of Investor Interest In Biopharma As It Raises $173m Fund
New Raise Exceeds $150m Goal To Back Incubated Start-Ups
With its new fund for companies emerging from Foresite Labs, Foresite Capital has raised more than $1bn in new venture capital during the past year to back life science and health care innovation.
You may also be interested in...
Cash is available for start-up, growth-stage and public companies through Texas Medical Center’s newly doubled venture fund, a pandemic preparedness initiative and new VC funds. In recent financings, Nutcracker closed a $167m series C round and 2Seventy raised $170m in a private placement.
Headwinds may be growing for private company investment, but investors at the BIO CEO & Investor conference remain optimistic about the general outlook.
There have been no biopharma initial public offerings in the US since 12 January while the industry’s valuations have plummeted by double digits since the start of 2022. Nevertheless, venture capital investment continues at a fast pace and there have been some follow-on public offerings.